EN DE
Watch EirGenix Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

EirGenix Inc. (6589) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of EirGenix Inc. stock TWD 40.83, price TWD 53.00, that is 23.0% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

EI EirGenix Inc. logo Thin data Nov 17, 2026

EirGenix Inc.

6589 · TW

Expensive (fair value 23% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Ranks above peers (6/10) 
Revenue last quarter +35% vs. a year ago. 
Quality 50/100 
Fair value 40.83 TWD · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 3y −12.1 %/yr in TWD) 
Loss-making · -46.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch EirGenix Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

178.00 TWD 40.55 TWD Fair Value 40.83 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range 40.55 TWD – 178.00 TWD · fair‑value band 30.62 TWD – 51.03 TWD · the 53.00 TWD price screens above the 40.83 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow EirGenix in your weekly email

Every Wednesday you see whether EirGenix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.

Show moreShow less

It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.

In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

Stock analysis

EirGenix Inc. (6589) currently trades at 53.00 TWD, while our estimate is 40.83 TWD, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 30.62 TWD (bear) to 51.03 TWD (bull), the price of 53.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

EirGenix Inc. reported revenue of 1.0B TWD in FY2025 versus 1.7B TWD in FY2021, a compound −12.3%/yr. Reported net income was −761M TWD in FY2025.

Key figures

Market cap 16.1B TWD (≈ $486M) Small · P/S ratio 13.7 · EPS (TTM) −1.89 TWD · Net margin −46.9% · Return on equity −7.0% · Return on assets (EBIT) −5.6% (5-year average) · Operating margin −70.7% · Revenue (TTM) 1.2B TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, 6589 screens richer than that median.

Fair Value

Bear 30.62 TWD Fair Value 40.83 TWD Bull 51.03 TWD
Price 53.00 TWD · Downside -23.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.4% (2021) → −83.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6589 screens overvalued: fair value 23% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare EirGenix Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −23.3% · Above median
Profitability
Return on assets −7.0% · Above median
Net margin (12 months) −46.9% · Below median
Operating margin (12 months) −70.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 35.4% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.93× · Cheaper than median
P/S (12 months) 13.28× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 6589
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 6589
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 6589
argenx SE ARGX $950.95 $908.40 −4% vs 6589
CSL Limited CSL A$199.55 A$186.49 −7% vs 6589
Moderna, Inc MRNA $215.27 $135.64 −37% vs 6589
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 6589
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 6589
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 6589
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 6589

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

EirGenix Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "EirGenix Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6589

Frequently asked questions

Is EirGenix Inc. (6589) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is 40.83 TWD versus a price of 53.00 TWD, about 23% lower (overvalued).
What is the fair value of 6589?
Our estimate for EirGenix Inc. is 40.83 TWD (as of Nov 17, 2026), built from audited fundamentals. The current price: 53.00 TWD.
What is the quality score of 6589?
EirGenix Inc. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EirGenix Inc. (6589)?
Our calculated price target is the estimate of 40.83 TWD (as of Nov 17, 2026). Cautious scenario 30.62 TWD, optimistic scenario 51.03 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the EirGenix Inc. stock forecast for 2026?
Our estimate puts fair value at 40.83 TWD, about 23% lower versus a price of 53.00 TWD (overvalued). Cautious scenario 30.62 TWD, optimistic scenario 51.03 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of EirGenix Inc. (6589)?
EirGenix Inc. reported trailing-twelve-month revenue of about 1.2B TWD (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of EirGenix Inc. (6589)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EirGenix Inc. it is 40.83 TWD per share (as of Nov 17, 2026), against a price of 53.00 TWD.
Is EirGenix Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, 6589 trades above its calculated fair value: price 53.00 TWD, fair value 40.83 TWD, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6589?
No. The price is what the market pays today (53.00 TWD); the fair value is what the company's own numbers justify (40.83 TWD). For EirGenix Inc. the two are 12.17 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is EirGenix Inc. worth?
The market values EirGenix Inc. at about 16.1B TWD (market capitalisation, as of Nov 17, 2026). Per share that is 53.00 TWD; our models calculate a fair value of 40.83 TWD per share.
What do the bullish and bearish scenarios say about 6589?
Our models span a range for EirGenix Inc.: cautious scenario 30.62 TWD, base 40.83 TWD, optimistic 51.03 TWD per share (as of Nov 17, 2026, price 53.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EirGenix Inc. (6589)?
Balance-sheet figures for EirGenix Inc. (as of Nov 17, 2026): return on equity −7.0%, debt of 0.11 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 6589 from its 52-week high?
EirGenix Inc. trades at 53.00 TWD, about 31% below its 52-week high of 76.50 TWD and 31% above the low of 40.55 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 40.83 TWD is for.
Which stocks are comparable to EirGenix Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EirGenix Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price 53.00 TWD, calculated fair value 40.83 TWD (−23%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. EirGenix Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EirGenix Inc. (6589)?
The closing price on Nov 17, 2026 was 53.00 TWD. Our estimate is 40.83 TWD, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EirGenix Inc. right now?
The price sits above even our optimistic bull case (51.03 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of EirGenix Inc.

How large is the market capitalisation of EirGenix Inc. (6589)?
The market capitalisation of EirGenix Inc. is 16.1B TWD (≈ $486M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EirGenix Inc. (6589)?
The price-to-sales ratio of EirGenix Inc. is 13.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EirGenix Inc. (6589)?
Earnings per share at EirGenix Inc. are −1.89 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EirGenix Inc. (6589)?
The net margin of EirGenix Inc. is −46.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EirGenix Inc. (6589)?
The return on equity (ROE) of EirGenix Inc. is −7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EirGenix Inc. (6589)?
On an EBIT basis the return on assets of EirGenix Inc. is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EirGenix Inc. (6589)?
The operating margin of EirGenix Inc. is −70.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EirGenix Inc. (6589)?
Revenue at EirGenix Inc. is growing 35.4% versus a year earlier (3y avg −12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does EirGenix Inc. (6589) generate?
The free cash flow of EirGenix Inc. is −1.3B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch EirGenix Inc. in the live analysis

One click puts EirGenix Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.